Seagen
在场
是其中之一......
- Forbes Global 2000 (#436);
- Fortune 500 (#69);
- Global Fortune 500 (#236);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Pfizer 是一家在股票代码 PFE (US) 下上市的公司。
Pfizer 在 39 个国家有直接业务。Pfizer 拥有 46家子公司，其中包括 Pfizer Asia、Pfizer Australia 和 Pfizer Austria。
他们在：
涉及Pfizer的并购和融资。
- Pfizer 已收购 Seagen (公布2023十二月12号).
- Pfizer has announced the acquisition of Seagen (公布2023三月13号).
- Pfizer has announced the acquisition of Seagen (公布2023二月27号).
高管
查看带有其 9 名主要高管的组织结构图
Seagen 搜索最多的简介
- Vaughn Himes, Chief Technical Officer
- Charles Romp, Executive Vice President, Commercial
- Peggy Pinkston, Chief Human Resources Officer
高管在Pfizer变化
- Chris Boshoff 曾任 Chief Oncology Research and Development Officer and Executive Vice President, 将于 20251月1 升职为 Chief Scientific Officer and President of Research & Development (新闻发布的2024十一月21号).
- Tim Buckley已作为Director加入公司 (新闻发布的2024十月15号).
- Mikael Dolsten, Chief Scientific Officer and President, Research & Development 请很快离开公司 (新闻发布的2024七月9号).
创建提醒
跟踪 Seagen 的高管变动
生物技术
Pfizer 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
Seagen 的最新新闻稿
- Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
- Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
- Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023
- Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
- Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
- Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
- Seagen Stockholders Approve Acquisition by Pfizer
- News, Events, and Media Resources – Seagen
- Seagen Press Releases Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejf
- Seagen - Press releases
- View more press releases Close
关于 Seagen 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Natasha Hernday 
